Mioko Matsuo1, Ryuji Yasumatsu2, Muneyuki Masuda3, Satoshi Toh3, Takahiro Wakasaki1, Kazuki Hashimoto1, Masahiko Taura1, Ryutaro Uchi1, Takashi Nakagawa1. 1. Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. 2. Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Electronic address: yasuryuj@qent.med.kyushu-u.ac.jp. 3. Department of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
Abstract
OBJECTIVES: Immune-related adverse events (irAEs) have been shown to be associated with higher antitumor responses and a clinical benefit in non-small cell lung carcinoma, renal cell carcinoma, and melanoma patients. However, little is known regarding the association between irAEs and the clinical effect of nivolumab for recurrent/metastatic head and neck squamous cell carcinoma (R/MHNSCC). MATERIALS AND METHODS: We evaluated 108 patients treated with nivolumab for R/MHNSCC at 2 participating institutions. IrAEs were identified and profiled. We analyzed the association of each immune-related adverse effect with the clinical outcome of the patients. RESULTS: Among 108 patients, the objective response rate (ORR) was 29.6% (32/108 patients), and the disease control rate (DCR) was 50.0% (54/108 patients). IrAEs were observed in 41 patients (38.0%). Patients with irAEs had a significantly higher ORR and DCR than those without irAEs (46.3% vs. 19.4%, P = 0.004 and 75.6% vs. 34.3%, P < 0.001, respectively). The median progression-free and overall survival rates in patients with irAEs were significantly longer than in those without irAEs. CONCLUSIONS: There was a significant relationship between irAEs and efficacy in R/MHNSCC patients treated with nivolumab. Our results indicate that the development of irAEs may aid in the earlier prediction of anticancer effects in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.
OBJECTIVES: Immune-related adverse events (irAEs) have been shown to be associated with higher antitumor responses and a clinical benefit in non-small cell lung carcinoma, renal cell carcinoma, and melanomapatients. However, little is known regarding the association between irAEs and the clinical effect of nivolumab for recurrent/metastatic head and neck squamous cell carcinoma (R/MHNSCC). MATERIALS AND METHODS: We evaluated 108 patients treated with nivolumab for R/MHNSCC at 2 participating institutions. IrAEs were identified and profiled. We analyzed the association of each immune-related adverse effect with the clinical outcome of the patients. RESULTS: Among 108 patients, the objective response rate (ORR) was 29.6% (32/108 patients), and the disease control rate (DCR) was 50.0% (54/108 patients). IrAEs were observed in 41 patients (38.0%). Patients with irAEs had a significantly higher ORR and DCR than those without irAEs (46.3% vs. 19.4%, P = 0.004 and 75.6% vs. 34.3%, P < 0.001, respectively). The median progression-free and overall survival rates in patients with irAEs were significantly longer than in those without irAEs. CONCLUSIONS: There was a significant relationship between irAEs and efficacy in R/MHNSCC patients treated with nivolumab. Our results indicate that the development of irAEs may aid in the earlier prediction of anticancer effects in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.
Authors: Adam J Luginbuhl; Young J Kim; Andrew P South; Athanassios Argiris; Jennifer M Johnson; Larry A Harshyne; Alban J Linnenbach; Sanket K Shukla; Angela Alnemri; Gaurav Kumar; David M Cognetti; Joseph M Curry; Nikita Kotlov; Zoya Antysheva; Sandrine Degryse; Kyle Mannion; Michael K Gibson; James Netterville; Brandee Brown; Rita Axelrod; Ralph Zinner; Madalina Tuluc; Stacey Gargano; Benjamin E Leiby; Ayako Shimada; My G Mahoney; Ubaldo Martinez-Outschoorn; Ulrich Rodeck Journal: Clin Cancer Res Date: 2022-03-01 Impact factor: 12.531